Paul Eckburg

Paul Eckburg, M.D., an infectious diseases physician and Chief Medical Officer of AN2, has worked in clinical research and anti-infective drug development for over 20 years. Dr. Eckburg has served as acting CMO for Zavante Therapeutics, Geom Therapeutics, Utility Therapeutics, and Bugworks Research, among others. He has been involved in the development of multiple approved anti-infective products, including ceftaroline fosamil (Teflaro®), inhaled levofloxacin (Quinsair™), ceftazidime-avibactam (Avycaz®), and omadacycline (Nuzyra®). Dr. Eckburg received his Bachelor of Science in Cell and Structural Biology from the University of Illinois at Urbana-Champaign and his M.D. from Rush University. He completed both Internal Medicine residency and Infectious Diseases fellowship at Stanford University School of Medicine, where he continues to teach as an Adjunct Clinical Assistant Professor.